收藏切换
Progress in immune-related intestinal adverse effects induced by immune checkpoint inhibitors
收藏切换
Mengyun GU1, 2, Zhimin SUN3, 4, Zixuan YANG1, 2, Lei SHI1, 2, Minhui ZHENG1, 2, Naping TANG1, 2, *
World Clinical Drug | 2024, 45(11) : 1205 - 1211
Less
收藏切换
World Clinical Drug | 2024, 45(11): 1205-1211
• Review •
Progress in immune-related intestinal adverse effects induced by immune checkpoint inhibitors
Full
Mengyun GU1, 2, Zhimin SUN3, 4, Zixuan YANG1, 2, Lei SHI1, 2, Minhui ZHENG1, 2, Naping TANG1, 2, *
Affiliations
  • 1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203, China
  • 2.Shanghai Innostar Bio-Technology Co., Ltd., Shanghai 201203, China
  • 3.College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230000, Anhui Province, China
  • 4.Yangtze Delta Drug Advanced Research Institute, Yangtze Delta Pharmaceutical College, Nantong 226133, Jiangsu Province, China
Published: 2024-11-10 doi: 10.13683/j.wph.2024.11.015
Outline
收藏切换

Immune checkpoint inhibitor (ICI) has become one of the important methods in the treatment of advanced tumors, and has significant survival advantages. However, ICI is often associated with immune-related adverse events (irAE), among which intestinal adverse events (such as colitis) are more common. The main symptoms include diarrhea, abdominal pain and intestinal bleeding. Although intestinal irAE induced by ICI has similar intestinal immune response and medical history characteristics to inflammatory bowel disease, the course of the disease progresses rapidly, and usually involving antagonism of immune signaling pathway and dysactivation of T cells. ICI adverse events (AE) should be confirmed according to clinical manifestations and related examinations, and then treated according to the severity of symptoms. In recent years, a large number of studies based on high-resolution omics data and artificial intelligence technology, especially intestinal flora and in vitro intestinal organoid models, have provided new methods and tools for predicting and evaluating the efficacy of ICI, exploring the mechanism and treatment strategy of irAE.

immune checkpoint inhibitor  /  immune-related adverse events  /  colitis  /  gut microbes  /  intestinal organoids
顾梦芸, 孙智敏, 杨紫轩, 石磊, 郑敏慧, 汤纳平. 免疫检查点抑制剂诱导免疫相关肠道不良反应的研究进展. 世界临床药物, 2024 , 45 (11) : 1205 -1211 . DOI: 10.13683/j.wph.2024.11.015
Mengyun GU, Zhimin SUN, Zixuan YANG, Lei SHI, Minhui ZHENG, Naping TANG. Progress in immune-related intestinal adverse effects induced by immune checkpoint inhibitors[J]. World Clinical Drug, 2024 , 45 (11) : 1205 -1211 . DOI: 10.13683/j.wph.2024.11.015
Year 2024 volume 45 Issue 11
21
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.11.015
  • Receive Date:2024-05-24
  • Online Date:2026-11-17
  • Published:2024-11-10
Article Data
Affiliations
History
  • Received:2024-05-24
Affiliations
    1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203, China
    2.Shanghai Innostar Bio-Technology Co., Ltd., Shanghai 201203, China
    3.College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230000, Anhui Province, China
    4.Yangtze Delta Drug Advanced Research Institute, Yangtze Delta Pharmaceutical College, Nantong 226133, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.11.015
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT